Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BridgeBio’s $299m Gives It Two More Years Of Runway To Launch New Companies

Jan 24 2019

• By Joseph Haas

Dollar bills

Related Content

Start-up QED Touts Singular Focus On FGFR Inhibitor Infigratinib

Jun 06 2018

The Next Roivant Or Fortress? BridgeBio Raises $135m To Spin Out New Companies

Sep 18 2017

Roivant's New Respiratory-Focused Vant Adds Chronic Cough Candidate To The Portfolio

Sep 17 2018

Leo Lines Up PellePharm Buy In Rare Skin Cancer Deal

Nov 20 2018

Start-Up Eidos Surfs Crest Of TTR Amyloidosis Wave

Aug 27 2018

Deal Watch: BridgeBio To Launch New Subsidiary Around Rare Disease Candidate Obtained From Alexion

Jun 18 2018

Related Companies

BridgeBio Pharma, Inc.

Roivant Sciences Ltd.

Fortress Biotech Inc.

Ultragenyx Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

Novartis AG

LEO Pharma A/S

PellePharm, Inc.

Eidos Therapeutics, Inc.

Additional Topics

Financing Business Strategies Commercial Companies StartUps and SMEs BioPharmaceutical

More from Financing

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window